Annexin Pharmaceuticals: Strategy Update - Redeye

Tomorrow between 13:00-15:00, Annexin Pharmaceuticals' CEO, Anders Haegerstrand, Chief Scientific and Medical Officer, Anna Frostegård, and Head of Therapeutic Area Oncology, Alain Thibault, will present the company’s strategic priorities and its commercial roll-out. After the presentation, Redeye's analyst will moderate a Q&A.

Länk till analysen i sin helhet: https://www.redeye.se/events/882805/strategy-update-annexin-pharmaceuticals-2?utm_source=finwire&utm_medium=RSS